Bladder cancer treatment is undergoing a paradigm shift with the expanding role of immunotherapy, particularly in muscle-invasive bladder cancer (MIBC), where traditional approaches have shown limited efficacy. This symposium brings together leading clinicians to explore how immunotherapy is reshaping treatment standards and improving patient outcomes across different disease stages. [para] Our expert panel will examine the latest clinical trial evidence supporting novel immunotherapy-based strategies, providing practical insights for personalizing treatment approaches in MIBC. Through interactive case-based discussions, participants will gain valuable perspectives on tailoring immunotherapy for individual patients, optimizing therapeutic outcomes while managing treatment-related considerations. This program will also spotlight emerging opportunities in early-stage bladder cancer, where immunotherapy is showing promising potential to transform patient care.